Document Detail


Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
MedLine Citation:
PMID:  20351653     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare the intraindividual differences of dynamic signal characteristics for 3 gadolinium chelates (gadopentetate dimeglumine [Gd-DTPA], gadodiamide [Gd-DTPA-BMA], and gadobenate dimeglumine [Gd-BOPTA]) using dynamic contrast enhanced magnetic resonance (MR) imaging (DCE-MRI) with a preclinical beagle model at 7 Tesla. METHOD AND MATERIALS: Seven beagles were scanned 3 times each with a 7-day interval between the scans on a 7T whole body MRI system (Achieva, Philips) using a T/R head coil. Three different Gd contrast agents including Gd-DTPA, Gd-DTPABMA, and Gd-BOPTA were injected in a randomized order with a power injector (Spectris, MedRad, Indianola, PA) using dose of 0.1 mmol/kg body weight and flow rate of 0.06 mL/s. During image acquisition and data analysis, the identity of the specific contrast agent used for each examination was blinded. A 3D RF-spoiled fast field echo sequence was used for dynamic scans with in-plane spatial resolution 0.47 x 0.47 mm(2), temporal resolution of 9.5 seconds, and a total of 60 time points. Regions of interest were drawn within the carotid arteries and muscle tissue to determine semiquantitative parameters including maximum enhancement ratio, area under the signal enhancement curve over 90 seconds after contrast injection (AUC_90), time to maximum signal enhancement (T(max)), and washout_score. Additionally, quantitative pharmacokinetic parameters were measured in muscle tissues by applying 3 separate 2-compartment models; (1) artery input function (AIF) based Tofts model, (2) Brix model without AIF, and (3) AIF decomposed refined Brix model. RESULTS: Gd-BOPTA produced higher signal to noise ratio on postcontrast T1- weighted images than the other 2 Gd based contrast agents at 7T. Quantitatively, Gd-BOPTA provided a significantly higher maximum enhancement ratio (P < 0.01), AUC_90 (P < 0.01) and washout_score (P < 0.01) in beagle musculature and cranial vasculature compared with both Gd-DTPA and Gd-DTPA-BMA. Among all the quantitative pharmacokinetic parameters, only the exchange rate constants (kep) calculated from these 3 models did not show a significant difference among the various contrast agents. CONCLUSIONS: Gd chelate containing MR contrast agents can be used at 7T for DCEMRI. Gd-BOPTA demonstrates stronger signal enhancement than standard Gd chelates, in concordance with the results of studies at lower fields. The observed enhancement characteristics for the 3 contrast agents demonstrate that the pharmacokinetic parameter kep is more robust in various models using DCE-MRI than the other pharmacokinetic parameters. This information is important relative to multisite clinical trials and long-term clinical studies that often use several different contrast agents and different models.
Authors:
Jiachao Liang; Steffen Sammet; Xiangyu Yang; Guang Jia; Yukihisa Takayama; Michael V Knopp
Related Documents :
2255233 - Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium...
12876703 - Combination of transfection agents and magnetic resonance contrast agents for cellular ...
15617593 - Introducing a freely accessible internet database for identification of cerebral aneury...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Investigative radiology     Volume:  45     ISSN:  1536-0210     ISO Abbreviation:  Invest Radiol     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-15     Completed Date:  2010-07-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0045377     Medline TA:  Invest Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  233-44     Citation Subset:  IM    
Affiliation:
Department of Radiology, The Ohio State University, Columbus, OH 43210, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Contrast Media / pharmacokinetics*
Dogs
Gadolinium / pharmacokinetics*
Gadolinium DTPA / pharmacokinetics
Individuality
Magnetic Resonance Imaging / methods*
Meglumine / analogs & derivatives,  pharmacokinetics
Organometallic Compounds / pharmacokinetics
Whole Body Imaging
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Organometallic Compounds; 113662-23-0/gadobenic acid; 122795-43-1/gadodiamide; 6284-40-8/Meglumine; 7440-54-2/Gadolinium; 80529-93-7/Gadolinium DTPA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gadofosveset-Enhanced Magnetic Resonance Imaging of Human Carotid Atherosclerotic Plaques: A Proof-o...
Next Document:  Using Standard Nonenhanced Axial Scans for Cerebral CT Angiography Bone Elimination: Feasibility Stu...